Skip to main content
OpenTrials
Completed

NCT Number: NCT07728604

Effect of Digital Follow-up Supported Patient Education on Immunosuppressive Medication Adherence and Quality of Life After Liver Transplantation

This randomized controlled study aimed to evaluate the effect of digital follow-up supported patient education on immunosuppressive medication adherence and quality of life in adult liver transplant recipients. Participants in both groups received standard discharge education. The intervention group additionally received structured digital follow-up messages for 12 weeks, while the control group received standard care only. Medication adherence and quality of life were assessed before and after the intervention using validated questionnaires.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Acibadem İzmir Kent Hospital

Izmir, 35620, Turkey (Türkiye)

About this study

Lifelong adherence to immunosuppressive medication is essential for preventing graft rejection and maintaining long-term graft survival after liver transplantation. However, medication non-adherence remains a common problem and may negatively affect patient outcomes and quality of life. Digital follow-up interventions may improve adherence by providing regular reminders and educational support after discharge.

This single-blind randomized controlled trial was conducted at the Liver Transplant Center of Acibadem Kent Hospital, İzmir, Türkiye. Adult liver transplant recipients who met the eligibility criteria were randomly assigned to either a digital education group or a control group. All participants received standard discharge education. In addition, participants in the intervention group received structured digital follow-up messages for 12 weeks. The control group received routine follow-up care only.

The primary outcome was immunosuppressive medication adherence, assessed using the Immunosuppressive Medication Adherence Scale (MMAS-8). The secondary outcome was quality of life, assessed using the Chronic Liver Disease Questionnaire (CLDQ 2.0). Outcomes were evaluated before the intervention and at the end of the 12-week follow-up period.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or older.
  • Having undergone liver transplantation.
  • Currently receiving immunosuppressive therapy after liver transplantation.
  • Ability to read and write in Turkish.
  • Ability to use a smartphone to receive and follow digital messages.
  • Willingness to participate voluntarily in the study.
  • Provision of written informed consent.

Exclusion criteria

  • Experiencing an acute rejection episode during the study period.
  • Presence of cognitive, psychiatric, or communication problems that would interfere with participation in the study.
  • Inability to regularly follow digital messages.
  • Difficulty reading and understanding Turkish.
  • Inability to maintain communication throughout the study period.
  • Refusal to participate in the study.

Treatment and study plan

Digital Follow-up Supported Patient Education

Behavioral

Participants received standard discharge education followed by structured digital follow-up messages for 12 weeks to improve immunosuppressive medication adherence and quality of life.

Standard care

Other

Participants received routine discharge education and standard follow-up care. No additional digital follow-up messages or educational reminders were provided during the study period.

Primary outcomes

  1. Immunosuppressive Medication Adherence

    Time frame: Baseline and 12 weeks

    Immunosuppressive medication adherence was assessed using the Immunosuppressive Medication Adherence Scale used in this study.

Secondary outcomes

  1. Chronic Liver Disease Quality of Life Score (CLDQ 2.0)

    Time frame: Baseline and 12 weeks

    Quality of life was assessed using the Chronic Liver Disease Questionnaire (CLDQ 2.0).

Sponsors and collaborators

Lead sponsor

Cansu Yıldız

Other

Registry information

Official study title

Effect of Digital Follow-up Supported Patient Education on Immunosuppressive Medication Adherence and Quality of Life in Liver Transplant Recipients: A Single-Blind Randomized Controlled Trial.

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jul 27, 2026
Registry last updated
Jul 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.